P
Paul G. Richardson
Researcher at Harvard University
Publications - 1631
Citations - 174221
Paul G. Richardson is an academic researcher from Harvard University. The author has contributed to research in topics: Multiple myeloma & Bortezomib. The author has an hindex of 183, co-authored 1533 publications receiving 155912 citations. Previous affiliations of Paul G. Richardson include Broomfield Hospital & Dartmouth College.
Papers
More filters
Journal ArticleDOI
Incidence of Post-Hematopoietic Stem Cell Transplantation (HSCT) Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) without Hyperbilirubinemia at Diagnosis and Efficacy of Defibrotide in an Expanded-Access Program
Selim Corbacioglu,Nancy A. Kernan,Antonio Pagliuca,Robert O. Ryan,William Tappe,Paul G. Richardson +5 more
TL;DR: This post hoc analysis examines incidence of VOD/SOS without elevated bilirubin, and survival in defibrotide-treated, post-HSCT patients in the T-IND program (2007-2016).
Journal ArticleDOI
Health-Related Quality of Life Among Patients with Relapsed or Refractory Multiple Myeloma Who Received Pomalidomide, Bortezomib, and Low-Dose Dexamethasone Versus Bortezomib and Low-Dose Dexamethasone – Results from the Phase 3 Optimismm Study
Katja Weisel,Meletios A. Dimopoulos,Philippe Moreau,Münci Yağcı,Alessandra Larocca,Abraham S. Kanate,Filiz Vural,Nicola Cascavilla,Supratik Basu,Peter R. E. Johnson,Peter D. Byeff,Marek Hus,Paula Rodriguez Otero,Kosei Matsue,Ercan Muelduer,Pekka Anttila,Patrick Hayden,Maria-Theresa Krauth,Dina Ben-Yehuda,Larisa P. Mendeleeva,Shien Guo,Lea Purnomo,Xin Yu,Lara Grote,Tsvetan Biyukov,Mohamed H. Zaki,Paul G. Richardson +26 more
TL;DR: This analysis evaluated the effect of PVd versus Vd on HRQoL in patients enrolled in the OPTIMISMM study, which demonstrated that pomalidomide, bortezomib, and low-dose dexamethasone (PVd) resulted in a significantly longer progression-free survival (PFS) and greater overall response rate (ORR) in patients with relapsed or refractory multiple myeloma (RRMM).
Journal ArticleDOI
Allogeneic transplantation in multiple myeloma: a potential renaissance in the era of novel therapies?
TL;DR: 2. Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3,000 patients treated since 1989.
Journal ArticleDOI
OAB-045: COVID-19 vaccine responsiveness in patients with Multiple Myeloma and Waldenström Macroglobulinemia
Andrew R. Branagan,Matthew Lei,Andrew Yee,Elizabeth O'Donnell,Jorge J. Castillo,Noopur Raje,Steven P. Treon,Catherine A Flynn,Jill N. Burke,Cynthia C. Harrington,Emerentia Agyemang,Clifton C. Mo,Omar Nadeem,Paul G. Richardson,Allison Maebius,Chukwuamaka Onyewadume,Cristina Panaroni,Kirsten Meid,Zachary Bernstein,Rebecca Lyons,Matthew J. Waterman,Raquel Gallagher,Boris Juleg,Galit Alter,Shayna Sarosiek +24 more
TL;DR: In this paper, SARS-CoV-2 spike protein (S) antibodies were detected with the Elecsys assay (Roche Diagnostics) 28 days after final vaccination in patients with multiple myeloma and Waldenstrom macroglobulinemia.
Journal ArticleDOI
A First in Class APRIL Fully Blocking Antibody Targets Novel Immune Regulation of APRIL in Multiple Myeloma: Further Therapeutic Implication
Liang Lin,Lijie Xing,Chirag Acharya,Kenneth Wen,Phillip A Hsieh,John Dulos,Andrea van Elsas,Nikhil C. Munshi,Paul G. Richardson,Kenneth C. Anderson,Yu-Tzu Tai +10 more
TL;DR: This data suggests that the humanized APRIL monoclonal antibody 01A named BION-1301, which also potently reduces myeloma burden in SCID-hu mice, should be considered for human use.